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ABSTRACT
Statin drugs are a class of drug that work to reduce endogenous production of
cholesterol by competitively inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase
(Hmgcr) thus inhibiting production of mevalonic acid in the mevalonate pathway.
Atorvastatin (Lipitor) is one of the most widely prescribed statin drugs and contamination
of wastewater effluent is a growing environmental concern because of the potential to
interfere with steroidogenesis in wildlife. Amphibians may be particularly susceptible to
the effects of atorvastatin contamination because of their highly permeable integument. I
used an amphibian model, Xenopus laevis to test the hypothesis that chronic exposure to
low concentrations of atorvastatin in water has an adverse effect on steroid hormone
levels, growth and development. This hypothesis was tested via a series of toxicity
assays designed to evaluate potential endocrine disrupting effects of atorvastatin using
traditional aquatic toxicology assays combined with modern molecular biology
techniques to identify and report regulatory alteration of physiological pathways. Results
indicated significant dose-dependent upregulation of steroidogenesis as confirmed by
both qPCR and total RNA sequencing and supported by evidence of alteration of
testosterone and estradiol concentrations. Such effects have the potential to significantly
alter sex ratios in amphibian populations localized around wastewater effluent sites. This
research provides insight into the potentially harmful effects of relatively low
concentrations of aqueous atorvastatin.
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CHAPTER I – INTRODUCTION AND BACKGROUND
Statin drugs are a class of drug that work to reduce endogenous production of
cholesterol by competitively inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase
(Hmgcr) thus inhibiting production of mevalonic acid in the mevalonate pathway. This
results in reduced cholesterol biosynthesis in humans and helps to reduce high cholesterol
levels (hypercholesterolemia) and the risk of cardiovascular disease.
Atorvastatin (Lipitor) as one of the most widely prescribed statin drugs (Stagnitti,
2007). Since new statin drugs are created constantly, prescription rates and use have
likely declined, however atorvastatin remains one of the most highly prescribed
medications in the western world. A recent study of patients in the US Department of
Veteran Affairs found that 79% of all patients at their facilities were prescribed a statin of
some type (McBride et al., 2018). In the US, it is estimated that 27.8% of the population
40 years and older take statin medications, and the medical community widely considers
these rates to be considerably lower than target rates for a healthy population (Salami et
al., 2017). This is primarily due to the high rate of hypercholesterolemia in developed
countries for which atorvastatin is designed to treat by reducing endogenous production
of cholesterol.
1.1 Wastewater Effluent.
It has been suggested for quite some time that pharmaceutical contamination of
wastewater effluent is a growing environmental concern. Numerous studies report active
pharmaceutical compounds detected in both wastewater effluent and surface waters (Batt,
Kostich, & Lazorchak, 2008; Chen et al., 2006; Ort et al., 2010; Richards & Cole, 2006).
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The sources of these compounds vary from hospital input to improper disposal of expired
medications and residential sewage and agricultural runoff.
Modern engineering solutions to effectively remove pharmaceutical contaminants
from wastewater effluent are either too costly or impractical, and as a result,
pharmaceuticals continue to be discharged in wastewater effluent at increasing rates
(Halling-Sorensen et al., 1998). While designs of wastewater treatment plants vary from
activated sludge digestion to spray field irrigation, almost all wastewater treatment
methodologies involve mechanical, photochemical, and biological filtration. Photo
degradation accounts for some removal of pharmaceuticals, but it is not significant
enough to reduce pharmaceutical levels below detectable levels. A recent study of 3
conventional wastewater treatment plants in Spain over a 2-year period showed removal
rates of ~50%, with atorvastatin effluent concentrations in the 2 ng L-1 range (Jelic et al.,
2011). Moreover, accumulation in lakes and streams in locations near effluent sites is not
uncommon.
Concentrations of atorvastatin ranging from 1-4 μg L-1 have been detected in
waters adjacent to effluent sites in Canada (Lee, Peart, Svoboda, & Backus, 2009). As
these chronic low levels of atorvastatin are continuously discharged into the surrounding
ecosystem, small aquatic organisms such as fish and amphibians are exposed, and
potentially affected by atorvastatin. Little is known about environmental degradation of
atorvastatin. A 2005 study of photodegradation of atorvastatin suggested an
environmental half-life of 0.6 – 2.4 hours in surface water and noted that
photodegradation is enhanced in the presence of dissolved organic matter(Lam &
Mabury, 2005). While this short half-life is favorable to the environment, high influent
2

rates of atorvastatin to wastewater treatment plants allow for replacement of degraded
atorvastatin resulting the localized concentrations near wastewater effluent sites.
1.2 Endogenous Production of Cholesterol.
In humans, LDL/HDL cholesterol ratios are inflated in large part, due to
endogenous production of cholesterol (Kapourchali, Surendiran, Goulet, & Moghadasian,
2016). Hypercholesterolemia is caused by high levels of LDL cholesterol proportional to
HDL cholesterol in the body (Kapourchali et al., 2016).
Endogenous cholesterol production occurs across 3 primary pathways. These
pathways are fatty acid metabolism, the mevalonate, or isoprenoid, pathway, and the
squalene synthesis pathway (Figure 1.1).

3

Figure 1.1 Cholesterol biosynthesis and regulation of the mevalonate pathway
(Gruenbacher & Thurnher, 2017).
The fatty acid metabolism pathway converts carbohydrates via glycolysis, and lipids via
β-oxidation into acetyl coenzyme A (Acetyl-CoA). Next, the mevalonate pathway
converts Acetyl-CoA into isopentenyl pyrophosphate (IPP) and dimethylallyl
pyrophosphate (DMAPP). IPP and DMAPP are then used in the squalene synthesis
pathway for conversion into cholesterol.
In this general overview of endogenous cholesterol production, the mevalonate
pathway can be considered the rate limiting step in conversion of fatty acids to
4

cholesterol. For animals with potentially low input of dietary cholesterol, this could
reduce cholesterol levels significantly because endogenous production of cholesterol
accounts for two thirds of all cholesterol in the body (Kapourchali et al., 2016).
Atorvastatin blocks endogenous production of cholesterol by competitively inhibiting the
active site of Hmgcr. This effectively blocks conversion of fatty acids to cholesterol and
reduces the LDL/HDL ratio as treatment for hypercholesterolemia. An animal exposed
to atorvastatin could experience hypocholesterolemia due to the reduced ability of the
body to effectively regulate endogenous production of cholesterol to compensate for
decreased dietary input such as in amphibians.
In amphibians, dietary cholesterol input has a far less significant contribution to
overall cholesterol level than in the human model (Hadfield, Clayton, & Barnett, 2006).
This is because amphibians, and frogs in particular, tend to rely on diets based heavily on
plant matter and insects that contribute little to endogenous cholesterol levels(Hadfield et
al., 2006). This natural high protein/low fat diet combined with naturally low body fat
reserves suggests that shutting down endogenous cholesterol production via exposure to
statin drugs could adversely affect frogs in ways not evident in humans.
1.3 Pharmacology and Pharmacodynamics of Atorvastatin.
Atorvastatin was developed to combat the hypercholesterolemia epidemic that
currently plagues modern societies. Hypercholesterolemia, and by extension
atherosclerosis and coronary heart disease are one of the leading causes of death in
developed countries. Indeed, among the US population, heart disease is the leading cause
of death, and has held this top spot for quite some time (CDC, 2019). This study shows
that between 1999 and 2017 over 12 million deaths in the US were associated with
5

diseases primarily treatable by statin drugs. Atorvastatin, and statin drugs in general,
work to reduce endogenous production of cholesterol and, in turn, reduce mean total
cholesterol in the body. The prescribed dosage range in humans of atorvastatin is 10-80
mg/day (Lennernäs, 2003). Since the mass of an average human is approximately 80 kg,
mathematically, this resolves to be a concentration of 0.125-1 mg kg-1 of body mass. At
this dosage, smaller aquatic species undergoing chronic exposure have the potential to
reach circulating atorvastatin concentrations in the range of efficacy for atorvastatin.
In humans, atorvastatin is administered orally as a tablet in the calcium salt form
of the hydroxyl acid. Metabolism and uptake of atorvastatin occurs primarily in the gut.
At the physiologically relevant pH of 6, the solubility of the acid form is high, and as a
result, uptake into the intestinal lumen is high. The uptake mechanism of atorvastatin
calcium is complex and not well understood. Atorvastatin is administered in its active
form, and given its high lipophilicity (logKo/w = 6.36) (National Center for Biotechnology
Information, n.d.), absorption across the gut wall is assumed to be rapid with the bulk of
the uptake driven primarily by passive diffusion across the intestinal lumen and into the
enterocyte. Following uptake, atorvastatin serves as a substrate for Cyp3a4 in the
intestinal lumen. The protein encoded by cyp3a4 metabolizes a wide range of
pharmaceuticals and is useful as a biomarker indicating uptake and metabolism of
atorvastatin. When atorvastatin is administered, the acid undergoes glucuronidation and
is converted to its lactone form. The lactone has a much higher affinity for the Cyp3a4
protein, and conversion from the active acid form to the inactive lactone form in the liver
is considered to be the primary route of elimination (Jacobsen et al., 2000). The Cyp3a4
protein converts both the lactone and acid forms into their oxidized and μ-oxidized forms,
6

respectively. With respect to the acid forms, Cyp3a4 converts the open acid to 2-hydroxy
atorvastatin acid and 4-hydroxy atorvastatin acid. Of the two, 2-hydroxy atorvastatin
acid is the dominant acid metabolite (Jacobsen et al., 2000). Figure 1.2 shows a
hypothetical metabolic pathway for atorvastatin (Lennernäs, 2003).

Figure 1.2 Hypothetical representation of the metabolic pathways associated with
CYP3A4 metabolism of atorvastatin (Lennernäs, 2003).
Once inside the human body, it has a low bioavailability of 14% with serum
concentrations reaching tmax within 1.5 hours of the initial dose (Gibson, Stern, Abel, &
Whitfield, 1997). This high uptake and low bioavailability of atorvastatin allow
comparatively high levels of the active compound to be excreted from the body via urine
and feces. Repeated dose studies show that steady state is achieved within the first 72
hours, increases proportional to dose, and the remaining 70-80% of the dose is excreted
as the parent compound within 11 to 14 days (Black et al., 1999; Cilla Jr., Whitfield,
Gibson, Sedman, & Posvar, 1996).
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Once metabolized and inside the body, atorvastatin works as a competitive
inhibitor of Hmgcr. This competitive inhibition leads to decreased mevalonate levels,
and consequently, reduced endogenous production of cholesterol. As mevalonate levels
drop, upregulation of the genes encoding for Hmcgr are seen. This is one of several
feedback loops regulating mevalonate production and makes the hmgcr gene a useful
biomarker indicating exposure to atorvastatin. Multiple studies show evidence of dose
dependent reductions in LDL-cholesterol as well as reductions in mean total cholesterol
following administration of statin drugs in humans. (Cilla Jr. et al., 1996; Nawrocki et
al., 1995).
In general, statin drugs show a wide variety of beneficial effects in humans.
These beneficial effects include reduction in inflammation and reduced cholesterol
plaque build-up in arterial walls (Lennernäs, 2003). These beneficial effects come with
relatively few harmful side effects in humans, however, little work has been done to
assess potential harmful side effects to atorvastatin exposure and associated cholesterol
reduction in non-target species such as amphibians.
1.4 Steroidogenesis.
If exposure to environmental statins reduces circulating cholesterol levels in
amphibians, it is possible that this reduction affects circulating hormone levels as well.
In broad terms, cholesterol serves as a precursor molecule for steroidogenesis, following
a well-described pathway (Figure 1.3). This pathway is responsible for conversion of
cholesterol to the sex steroids estradiol and testosterone, in addition to production of the
stress hormone cortisol. It is the close connection between cholesterol and sex steroid
production that is the impetus for this study.
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Figure 1.3 The steroidogenesis pathway (Miller, 2018).
The rate-limiting step in steroidogenesis is conversion of cholesterol to
pregnenolone via enzymatic reaction with cholesterol side-chain cleavage enzyme
(P450scc). This reaction is mediated by Steroidogenic Acute Regulatory protein (Star),
which functions to move cholesterol from the outer mitochondrial membrane to the inner
mitochondrial membrane where the P450scc reaction takes place. Since Star is believed
to be constitutively expressed, and cholesterol availability is unlikely to be an issue, it is
the rate at which P450scc can synthesize pregnenolone that determines substrate supply
in subsequent reactions.
Pregnenolone then serves as the primary substrate for production of all steroids.
As pregnenolone levels decrease, so do levels of testosterone and estradiol. Additionally,
since pregnenolone also serves as a substrate for cortisol, stress has the risk to exacerbate
the crisis of low pregnenolone and by association, cholesterol. These factors combine to
9

suggest that atorvastatin can have endocrine disrupting effects by altering the production
of cholesterol critical for steroid synthesis.
1.5 Amphibian Toxicology.
Some amphibians, including Xenopus laevis, have an increased sensitivity to
aquatic toxins due to cutaneous respiration (Feder & Burggren, 1985). Premetamorphosis tadpoles use gills and cutaneous respiration to supplement oxygen needs
due to the high metabolic demands of metamorphosis. This provides an additional
exposure route to aquatic toxins and allows for greater potential for uptake into the
bloodstream. This is particularly problematic with regards to cutaneous respiration as the
cutaneous membrane in these amphibians provides little barrier to environmental
xenobiotics. As a result, amphibians have an enhanced sensitivity to chemicals in water
(ASTM INTERNATIONAL, 2012).
If statins act in a similar way in amphibians as they do in humans, environmental
exposure to atorvastatin could produce hypocholesterolemia, resulting in a net reduction
of steroid hormone production, endocrine disruption, and at its most extreme, alteration
of sexual differentiation and metamorphosis. Cholesterol is the primary substrate used in
the endogenous production of testosterone, and estradiol (Miller & Auchus, 2011). In
amphibians, endocrine disruption has been shown to alter sex ratios by affecting gonad
differentiation (Miyata & Kubo, 2000; Ohtani, Miura, & Ichikawa, 2000; Yu, Hsu, Ku,
Chang, & Liu, 1993). Many hormones produced via the cleavage of cholesterol also
drive the physiological processes for embryonic development and metamorphosis. A
recent study in zebrafish showed a 37% reduction in cholesterol, a 71% reduction in
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cortisol, a ~60% reduction in testosterone, and a ~20% reduction in estradiol as a result of
atorvastatin exposure (Al-Habsi, Massarsky, & Moon, 2015).
1.6 Amphibian Development.
Amphibians display a unique developmental apparatus that can be useful for
toxicity studies: metamorphosis. In 1967 Nieuwkoop and Farber published “Normal
table of Xenopus laevis”. This book served as the springboard into amphibian genetics
and teratogenesis assays. It laid out 66 developmental stages complete with criteria for
morphological analysis that could be used to determine growth stage in a non-invasive
manner. It defined times to each developmental stage at varying temperatures, making it
possible for researchers to determine alteration of amphibian development on a largescale basis and compare effects across laboratories.
Amphibians pass through four broad and generalized stages during development
(Figure 1.4). The embryonic stage is immediately following fertilization, and during this
time, embryos undergo cleavage, blastulation, gastrulation, neurulation, and tail-budding.
Upon completion of the embryonic stage, the animals are free swimming and feeding
tadpoles. In Xenopus laevis, this stage is complete in approximately 4 days.
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Figure 1.4 Developmental stages of amphibians with hormone mediation of
metamorphosis.
Taken from: http://www.mun.ca/biology/desmid/brian/BIOL3530/DEVO_13/ch13f19.jpg

Following the completion of the embryonic stages, the embryos transition into the
tadpole stage. The climax of this stage is defined primarily by metamorphosis. During
metamorphosis, tadpoles undergo several progressive and regressive changes and
extensive tissue remodeling. Hindlimb and forelimb development moves to completion,
and the tail resorbs into the body. Gills are resorbed into the body, and the lungs become
the primary respiratory organ. This stage comes with a variety of hormonal changes
necessary for engaging the appropriate cellular response for tissue differentiation.
Regulatory control of metamorphosis is mediated by the release of thyroxine (T4)
and triiodothyronine (T3) by the thyroid (Gilbert, 2007). Prolactin delays the onset of
metamorphosis until levels of T3 and T4 exceed the levels of prolactin. This creates a
positive feedback loop in that the high levels of T3 and T4 stimulate further release of T3
12

and T4 to push the animal through metamorphosis (Figure 1.4). Recent studies have
shown an interaction between estrogen and testosterone levels with respect to thyroid
function. The presence of high estrogen levels in thyroid tissues has been shown to cause
cell proliferation, and negatively affect production of thyroid hormones(Santin &
Furlanetto, 2011). Low levels of testosterone have also been shown to inhibit thyroid
secretion of T3 and T4 (Meikle, 2004). It is the interaction between the thyroid and sex
steroids that is a cause of concern with respect to frogs exposed to statins in the
environment, specifically alteration of testosterone and estrogen levels in
metamorphosing tadpoles. The interaction between sex steroids and the secretion of T3
and T4 suggests that alteration of hormone concentrations has the potential to alter
metamorphic rates.
I hypothesized that chronic exposure to low concentrations of atorvastatin in
water has an adverse effect on production of steroids regulating growth and development
of X. laevis. This was tested via a series of toxicity assays. These assays first examined
atorvastatin efficacy by evaluating biomarkers of exposure in a tightly controlled
environment at doses well above environmental relevance. Once the efficacy of the drug
was verified, a battery of assays were used to evaluate environmentally relevant doses
across multiple life stages to examine the effects of atorvastatin exposure on amphibian
steroidogenesis. Measures for the target and non-target effects of atorvastatin on X.
laevis will be expression of several relevant genes, cholesterol measurement, and
significant alteration of the steroidogenesis pathway.
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1.7 Experimental Design.
The complete experimental design consisted of 3 distinct assays intended to test
the effect of atorvastatin at different developmental endpoints and maximize data
collection.
The first assay was used to determine the effects and verify the biomarkers used
in follow-on assays. This assay followed the ASTM assay protocol for the Frog Embryo
Teratogenesis Assay Xenopus (FETAX)(ASTM INTERNATIONAL, 2012) with minor
modifications to assay termination to preserve samples for molecular analysis as
described in the materials and methods chapter. This assay is performed at extremely
high concentrations as defined by the FETAX protocol. The intent behind this assay was
to elicit an effect and measure that effect. This assay served to hone tools for future data
analysis and validate biomarkers for assays at lower concentrations.
The second assay was a chronic tadpole metamorphosis assay. This experiment
was a 60-day chronic flow-through exposure under environmentally relevant
concentrations of atorvastatin. Briefly, tadpoles (NF47) were exposed continuously for
60 days and time to and through metamorphosis was measured. At termination, tadpole
liver tissue was taken for follow up molecular analysis. This experiment showed effects
of chronic, low concentration exposures of atorvastatin in water to metamorphosing
tadpoles.
The final assay was a chronic 60-day exposure of male and female adults to
environmentally relevant concentrations of atorvastatin in water. This aqueous exposure
showed the long term, chronic effects of exposure to atorvastatin. Endpoints in this assay
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include transcriptional analysis of assigned biomarkers of exposure, and quantification of
cholesterol, testosterone, and estradiol levels in plasma.
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CHAPTER II – MATERIALS AND METHODS
2.1 Introduction.
The complete experimental design consisted of three distinct experimental assays.
The FETAX assay was employed to evaluate the effects of high doses of atorvastatin on
developing Xenopus sp. embryos. The metamorphosis assay integrated organismal
responses determined from the FETAX to determine the effects of aqueous atorvastatin
exposure at environmentally concentrations on metamorphosing tadpoles. Finally, the
adult exposure evaluated the effects of chronic low concentrations of atorvastatin on adult
X. laevis.
2.2 FETAX.
The Frog Embryo Teratogenic Assay (FETAX) is an acute 96-hour exposure to
evaluate the effects of xenobiotic exposure during early life stages. The protocols and
procedures used in this experiment were a modification of the “Standard Guide for
Conducting the Frog Embryo Teratogenesis Assay-Xenopus (FETAX)”(ASTM
INTERNATIONAL, 2012). The FETAX follows the strictest of standards based on
decades of research data, as such, these standards are ideal for testing the response of
Xenopus sp. to xenobiotic exposure. The FETAX uses primarily morphometric data
endpoints to determine growth and developmental effects of exposure. The standard
protocol advises fixing the tadpoles in formalin for later analysis. This termination
protocol would not preserve tissue in a manner useful for follow-on molecular analysis.
In order to preserve the tissue in a manner more conducive to our needs, I have modified
the termination procedure by preserving the samples either in RNALater for later
extraction and analysis or by flash freezing for cholesterol analysis.
16

Briefly, embryos were collected and dejellied immediately following fertilization.
Normal embryos between NF stage 8 and 11 were selected and randomly distributed into
petri dishes. A selection of 5 increasing concentrations, determined using the ASTM
selection criteria, plus a control were set-up with 4 replicates. The embryos were then
allowed to grow out for 96 hours in a temperature-controlled incubator at 28°C under
constant supervision. At termination, images of each tadpole were taken for
morphometric analysis, and whole organisms were flash frozen for cholesterol
quantification or stored in RNALater for qPCR analysis.
2.3 Metamorphosis Assay.
The metamorphosis experiment was a chronic 60-day exposure to evaluate effects
during metamorphosis and growing into adulthood. The test was conducted with a
control and 3 treatments (n=30) in duplicate. Frogs were exposed to aqueous
concentrations of atorvastatin for the duration of the 60-day experiment. At termination,
the froglets were staged to allow for morphometric analysis, and liver samples were taken
for cholesterol quantification and qPCR analysis.
Tadpoles were commercially purchased from Xenopus Express and stage selected
to be NF 47 at shipment. Tadpoles were shipped overnight and acclimated to room
temperature upon arrival. Following acclimation, tadpoles were stage selected again to
be NF 47 at test initiation. Tadpoles were then sorted into 100 mL beakers (n=40) and
the beakers were covered with nytex mesh. The beakers were then placed into the flow
through exposure facility at the University of Southern Mississippi’s Gulf Coast Research
Laboratory. This unique facility allows continuous flow through exposures at a wide
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range of operating parameters. Table 2.1 describes the operational parameters of the
exposure system for the duration of this experiment.

Table 2.1 Flow through chamber operating parameters for the metamorphosis assay.
Temperature
Salinity
Dissolved
Oxygen
pH
Flow Rate
Residence Time
Stock Renewal
Frequency

22° C
0.15 ppt
8.5 mg L-1
7.5
1.5 L hr-1
20 hr
48hr

Stock solutions were prepared by first diluting atorvastatin calcium (CAS#:
344423-98-9) into DMSO at a concentration of 250 g/L. This primary stock was then
further diluted into a 10 g L-1 working stock for stock renewals. This working stock was
then diluted into appropriate stock concentrations and volumes for exposure chamber
protocols.
The exposure facility then continuously dilutes stock solutions and flows it
through the exposure tanks as the prescribed flow rate. Water samples were taken at
initiation, 30 days, and termination. These water samples were analyzed by Mississippi
State Chemistry Laboratory using LC/MS-MS for validation of dosing concentrations.
Water quality was monitored continuously using the built-in sensor array and
verified daily using a handheld YSI Quatro. As tadpoles grew, they were moved to a
larger enclosure weekly. Tadpoles were fed Xenopus Express tadpole crumble food for
the duration of the experiment. Initially, 1 pellet of crumble food per tadpole was left to
soak for 1 hour in clean system water and once dissolved, the entirety of the liquid food
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was fed to the tank. Animals were left at room temperature outside of flow-through
conditions for 1 hour following feeding then returned to the flow-through chamber. As
the tadpoles grew, an increasing amount of food was fed, and whole pellets were fed after
tadpoles had transitioned from gills to lungs. Tanks were cleaned biweekly by siphoning
out waste and detritus. Frogs were observed daily, and any injured or dead frogs were
removed from the tank.
2.4 Adult Chronic Assay.
The chronic adult exposure was a 60-day flow-through exposure intended to
investigate the response of adult frogs to chronic, low dose aqueous exposures at
environmentally relevant concentrations. Frogs were ordered from Xenopus Express and
shipped overnight. Upon arrival frogs were placed in 1cm of water and allowed to warm
to room temperature for 30 minutes.
After the initial warming period, frogs were placed in individual 1 L tanks of
water and visually inspected for any sign of injury or illness. Following visual
inspection, frogs were transferred to 20 L holding tanks segregated by sex. The animals
were physically isolated in the holding tanks, however both tanks shared the same water.
The holding tanks were 30 L continuous flow holding tanks running at a flow rate of
approximately 1.5 L/hr. Tank water was UV sterilized, mechanically filtered, and
temperature adjusted artesian well water. Water testing performed within 1 year of the
experiment verified that the water was within physical and chemical limits for
experimentation. The holding tanks were maintained at 21 ±3°C and on a 12h day/12h
night light cycle. Frogs were fed measured amounts of Zeigler Xenopus Diet 3 times
weekly. Males received 3 pellets each per feeding, and females received 6 pellets each
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per feeding. Approximately one hour after feeding, tanks were cleaned, and any uneaten
food was siphoned from the tanks.
Table 2.2 Flow through chamber operating parameters for the adult assay.
Temperature
Salinity
Dissolved
Oxygen
pH
Flow Rate
Residence Time
Stock Renewal
Frequency

22° C
0.15 ppt
8.5 mg L-1
7.5
1.5 L hr-1
20 hr
48 hr

Similar to the metamorphosis experiment, this experiment was run in the flowthrough exposure facility at the University of Southern Mississippi’s Gulf Coast Research
Laboratory. Exposure facility flow-through parameters can be found in Table 2.2. Water
quality was continuously monitored using the facility’s in-house sensor array and
checked daily using a YSI Quatro. Water samples were collected from the effluent tube
of the exposure tanks at set-up, 4 weeks, and termination. These samples were sent to
Mississippi State Chemical Laboratory for analysis via LC-MS/MS. At termination,
blood was drawn via cardiac puncture and plasma was separated and frozen, then the
frogs were euthanized via double pith and cervical dislocation. Immediately following
euthanasia, frogs were dissected, and liver, kidney, digestive tract, gonads, and spleen
were removed for follow up analysis.
Preserved samples were then used for qPCR, cholesterol analysis, and sex steroid
analysis. Samples used for qPCR underwent mRNA extraction using spin column
extraction (Qiagen #74106) and reverse transcription to cDNA using a RevertAid First
Strand cDNA Synthesis Kit (Thermo #K1621). Extracted cDNA was then used for qPCR
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to determine gene dysregulation as described in the molecular techniques. Samples
tested for cholesterol and sex steroids used associated protocols described in the
molecular techniques section of this document.
2.5 Molecular Techniques.
Spin column RNA isolation was performed following the RNeasy Mini Kit
(Qiagen #74106). Following extraction and isolation of mRNA, samples were reverse
transcribed using the RevertAid First Strand cDNA Synthesis kit (Thermo #K1621).
Following cDNA synthesis, samples were used in follow up qPCR reactions. Primers
were designed using Primer3 and purchased from Integrated DNA technologies. Primer
efficiencies are listed in Table 2.3. Quantitative PCR was performed on an Applied
Biosystems 7500 Fast Real-Time PCR system using Fast SYBR Green Mater Mix
(Applied Biosystems #4385612) and associated protocol.
Table 2.3 Primer efficiencies for primers used in qPCR reactions.
Primer
18s

Sequence
Efficiency
CGT CGC TAC TAC CGA TTG GA
96.45 %
CGC AGG TTC ACC TAC GGA AA
hmgcr
TGA TTG GCC GTA GGA AGA GC
95.68 %
TGG TGA TTG TGA AGC TCG GG
cyp3a4
GAG CCC ATT ACT CAT CTT AGT GGT
96.06%
CAC GTC CCG AGT GAT CTC C
cyp19a1
TGC ACG TCT CCT AAC TTT ACT GG
94.54 %
GAG TGG GAA CAG CTT CTG TGA
Lipid extraction from tissues for follow-on cholesterol quantification was
performed using a chloroform free Lipid Extraction Kit (abcam #ab211044). This
protocol was only used in the FETAX assay for extraction of whole-body cholesterol
from tadpoles. Cholesterol quantification was performed on plasma as well as tissue
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extract using Amplex Red Cholesterol Assay Kit (Thermo #A12216) and associated
protocol.
Testosterone and estradiol concentrations in plasma were measured using a
Testosterone ELISA Kit (abcam #108666) and 17 beta Estradiol ELISA Kit (abcam
#ab108667) respectively. These kits are designed for use in human plasma, therefore
both ELISA kits were validated using X. laevis plasma to verify hormone binding to the
antibody. Plasma used in the testosterone ELISA was diluted 100x and plasma for the
estradiol ELISA was dilute 1000x to keep all sample RFU measurements within the
standard curve.
RNA sequencing was performed on 6 samples at the University of Colorado’s
Core Microarray facility. The six samples were selected from the metamorphosis assay
and consisted of three control samples and three samples from the 4.4 ug L-1 treatment.
Briefly, RNA was isolated using the previously described protocol. Verification of RNA
integrity was performed using a NanoDrop 2000 to evaluate purity, and an Agilent
Bioanalyzer 2100 to evaluate RNA integrity. Once purity and integrity were determined
to be acceptable for sequencing, samples were shipped overnight in dry ice to the
University of Colorado. RNA sequencing and library preparation was performed on a
NovaSEQ 6000 using 2x150 paired end reads.
CLC Genomics Workbench (CLC) was used for initial data preparation and
mapping to the X. laevis reference genome (NCBI accession number:
GCA_001663975.1). Data preparation included removal of failed and low-quality reads
as well as adaptor trimming. Differential gene expression analysis was then performed
on the control versus the treatment group.
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Ingenuity Pathway Analysis (IPA) was used for determination of pathway
dysregulation. One of the limitations of IPA is that reference genes must be mapped to
their human ortholog as pathway data is not available for the amphibian genome. Since
molecular pathways are widely considered to be highly conserved across taxa, this
limitation was deemed to have a minimal impact on pathway analysis. The FDR cutoff
was set to 0.05, and pathway analysis was determined using expression fold change
determinations from CLC.
.
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CHAPTER III – FROG EMBRYO TERATOGENESIS ASSAY, XENOPUS
3.1 Introduction
The purpose for the FETAX assay in this project was to evaluate the uptake,
activity, and efficacy of atorvastatin in the amphibian model. Uptake was defined as
integration into the bloodstream. This is accomplished primarily by either osmosis via
cutaneous respiration or Cyp3a4 mediated transport across the intestinal lumen.
Atorvastatin activity was defined by upregulation of hmgcr and was a measure of
substrate binding activity allowing the drug to produce both target and non-target effects.
Substrate efficacy was defined as target effects produced downstream of the site of
activity and was be measured via cholesterol concentrations in tissue.
As previously discussed, the FETAX is an acute 96-hour assay. It is a highly
sensitive, highly studied experimental protocol useful in determining growth and
developmental abnormalities. Our purpose for choosing the FETAX protocol is its tight
experimental parameters and its ability to rapidly evaluate the effects of atorvastatin
exposure. Embryos were collected and dejellied immediately following fertilization.
Normal embryos between NF stage 8 and 11 were selected and randomly distributed into
petri dishes. A selection of 5 increasing concentrations determined from the FETAX
experimental protocol, plus a control and carrier control were set-up with replicates
(Figure 3.1). The embryos were grown out for 96 hours in a temperature-controlled
incubator at 28C under constant supervision with water changes every 24 hours. At
termination, images of each tadpole were taken for morphometric analysis, and the whole
organism was preserved for cholesterol quantification and qPCR analysis by flash
freezing in liquid nitrogen or storage in RNALater respectively.
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Control 1

Carrier
Control 1

3.696 mg/L
Atorvastatin

9.24 mg/L
Atorvastatin

23.1 mg/L
Atorvastatin

Control 2

Carrier
Control 2

3.696 mg/L
Atorvastatin

9.24 mg/L
Atorvastatin

23.1 mg/L
Atorvastatin

Control 3

Carrier
Control 3

Control 4

Carrier
Control 4

36.96 mg/L
Atorvastatin

59.136 mg/L
Atorvastatin

36.96 mg/L
Atorvastatin

59.136 mg/L
Atorvastatin

Figure 3.1 FETAX experimental design.
Frogs were bred as a single mated pair, and only the embryos from one single pair
were used in the experiment. Frogs were injected with 350 and 700 IU human chorionic
gonadotropin (HCG) for males and females respectively. Injections were given into the
dorsal lymph sac at a concentration of 1000IU/mL in sterile 0.9 % NaCl using a 26-gauge
needle. Twelve hours following injection, eggs were collected and dejellied immediately.
De-jellying embryos was performed as soon as egg collection was complete.
Eggs were transferred to a clean 1L beaker and swirled for ~2 minutes using de-jellying
solution described in the protocol(ASTM INTERNATIONAL, 2012). Once the jelly coat
was sufficiently removed, embryos were rinsed 3 times in FETAX solution(ASTM
INTERNATIONAL, 2012) and transferred to petri dishes for staging.
During staging and selection, embryos were double staged prior to selection for
experimentation. First embryos were selected for normal cleavage consistent with “Atlas
of Abnormalities”(Nieuwkoop P., 1994). Next embryos were selected that were between
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NF 8 and NF 11. If selected, embryos were moved to petri dishes of 25 embryos per dish
containing 10 mL FETAX solution.
Petri dishes were then randomly assigned to replicate groups. There were four
control replicates, four carrier control replicates, and 2 dishes for each concentration of
0.003696, 0.00924, 0.0231, 0.03696, and 0.059136 mg mL-1 respectively. Dishes were
then spiked with atorvastatin dissolved in DMSO, or DMSO only for carrier control.
Spike solution did not exceed 1% of FETAX solution volume, and was temperature
adjusted to 28C prior to introduction for petri dishes.
Dishes were then stored overnight in an incubator at 28C until renewal. Test
solution was completely replaced every 24 hours. Prior to renewal, the pH of the control
and the highest dose dishes was measured to monitor for large pH differences in the
presence of toxin. For renewal, all test solution was removed using a pasteur pipette with
an orifice large enough to allow the embryos to pass through to prevent damage. Next,
new test solution was then immediately poured into the dish. Dishes were then returned
to the incubator. This process was repeated daily for the duration of the 96-hour
experiment.
At test completion, dishes were photographed using a Nikon SMZ1500 dissecting
microscope fitted with a Nikon DXM1200C digital camera and embryos were euthanized
using a 2.5% v/v tricaine solution. Embryos were then transferred into 1.5 mL
microcentrifuge tubes containing 1 mL of RNALater. Tubes were allowed to rest at
room temperature for one hour to allow complete infiltration of preservative, then
transferred into -80C until downstream analysis.
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Validation of test concentrations was performed by spectrofluorimeter using a
previously validated method (Sharaf El-Din, Salama, Nassar, Attia, & Kaddah, 2012).
This method allowed simple, and rapid, same-day analysis of FETAX test solution to
monitor and verify test concentrations.
3.2 Endpoints and Protocols
Preserved embryos were used for qPCR and cholesterol analysis. Embryos used
for qPCR underwent mRNA extraction using spin column and reverse transcription to
cDNA. Extracted cDNA was then used for qPCR to determine gene dysregulation as
described in the molecular techniques section of this manuscript.
The FETAX assay in this project was intended to verify that the response of the
amphibian model is similar to the response in humans. As such, the biomarkers selected
for this assay were carefully designed to map directly to the human response to
atorvastatin exposure. The protein encoded by cyp3a4 is responsible for transporting
atorvastatin from the digestive system into the blood stream. Studies have shown that in
the presence of atorvastatin, cyp3a4 will be transcriptionally upregulated in order to
maintain sufficient enzyme in circulation (Willrich et al., 2013). In the FETAX assay I
expected to see a similar response in X. laevis with upregulation of cyp3a4 indicating
uptake of atorvastatin. Atorvastatin is a competitive inhibitor hmgcr, and exposure
causes transcriptional upregulation of the genes encoding for Hmgcr (Brown &
Goldstein, 2009). This provides a useful biomarker indicating activity of atorvastatin.
Finally, the target effect of atorvastatin is a reduction in circulating cholesterol
(Lennernäs, 2003). While this study is intended to investigate non-target effects of
atorvastatin, evaluating cholesterol levels serves as a measure of efficacy by determining
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if atorvastatin has reached circulatory concentrations high enough to elicit the targeted
response, in this case, reduction of circulating cholesterol. Eliciting this response is the
primary reason for the use of concentrations many orders of magnitude above
environmental relevance in the FETAX. If atorvastatin functions in amphibians in the
same manner as in humans the molecular signature should be similar to humans. This is
upregulation of cyp3a4 and hmgcr, and reduction of total cholesterol levels. Once
verified, this signature was then applied to follow-on studies for validation of atorvastatin
dosing in chronic aqueous assays.
3.3 Results and Discussion
3.3.1 Water Chemistry
Because I had previous data concerning aquatic toxicity of atorvastatin (Pfizer,
2018), I was able to skip the range finder test, and move directly to the definitive test in
the FETAX. Test concentrations tested were 0.03, 0.05, 0.08, 0.10, and 0.12 mg L-1.
These concentrations were defined based on the strict FETAX experimental protocol and
allow future comparisons to other FETAX data. I chose to take the lowest NOEC in the
available data, and test concentrations ranging down from that concentration. This
enabled us to test at the lowest possible concentrations and was particularly useful
considering the extremely low concentrations to be tested during the subsequent assays.
The mean atorvastatin concentrations measured daily at each water change were
0.0142, 0.0112, 0.0489, 0.0564, and 0.1193 mg L-1 (Figure 3.2). The test solution fell
into three statistically significant groups based on a One-Way ANOVA with Holm-Sidak
pairwise comparisons (p < 0.001 F = 20.98, df = 13). The control, carrier control,
0.0142, and 0.0112 mg L-1 concentrations were statistically similar, however they were
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different than all other groups. The 0.0489 and 0.0564 mg L-1 concentrations were
statistically similar, but significantly different than all other groups. The highest
concentration of 0.1193 mg L-1 was significantly different than all other groups. Based
on these data, molecular endpoints were evaluated for samples produced from the 0.0489
and 0.1193 mg L-1 concentrations as these concentrations were significantly different
from the controls.
FETAX Atorvastatin Concentrations
0.16

Atorvastatin Concentration (mg/L)

D
0.14
0.12
0.10
BC

0.08

BC

0.06
0.04

AB
AB

0.02
A
0.00
CC

T1

T2

T3

T4

T5

Treatment

Figure 3.2 Mean atorvastatin concentrations and standard error of atorvastatin in
exposure water immediately prior to water change.
Since I anticipated degradation of the atorvastatin over time for the duration of the
experiment, I measured the concentration of atorvastatin in solution via fluorescence
daily at water change (Figure 3.3). Overall, atorvastatin treated water saw a general
degradation over time. This is expected since atorvastatin concentrations were measured
prior to water change. The water had been in the exposure dishes for 24 hours, and some
degradation of the stock is not uncommon. The highest concentrations saw the greatest
decrease in statin levels over time. Collectively, all samples saw a degradation at each
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water change. This is probably caused by stock degradation. The FETAX protocol
requires a single stock solution created at the beginning of the experiment and used for all
subsequent water changes if possible, meaning that stock degradation may occur over
time.
FETAX Atorvastatin Concentration vs Time

Atorvastatin Concentration (mg/L)

0.14
Carrier Control
Treatment 1
Treatment 2
Treatment 3
Treatment 4
Treatment 5

0.12
0.10
0.08
0.06
0.04
0.02
0.00
-0.02
Day 1

Day 2

Day 3

Day 4

Figure 3.3 FETAX atorvastatin concentrations over time.
3.3.2 Molecular Endpoints
The metabolism and uptake of atorvastatin is mediated by the protein Cyp3a4.
The qPCR data indicate statistically significant and dose dependent upregulation of
cyp3a4 (Figure 3.4). The control and carrier control treatments were not significantly
different from each other but were statistically different from the atorvastatin treated
doses base on One-way ANOVA with Holm-Sidak pairwise comparison (p < 0.001, F =
25.56, df = 47,). This indicates that the carrier did not have a significant effect on
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transcriptional regulation of cyp3a4. The atorvastatin treatments of 0.0489 and 0.1193
mg L-1 were significantly upregulated relative to controls. The treated groups show
increasing upregulation as dose increased. This significant upregulation indicates dose
dependent metabolism of atorvastatin in the frog system as more Cyp3a4 protein is
produced to mediate uptake of atorvastatin as a greater concentration of substrate is
available.
CYP3A4 Expression
FETAX

4

(c)

Fold Change (Log2)

3
(b)
2

1
(a)
(a)
0

Control

Carrier

0.0489

0.1193

Exposure Concentration (mg/L)

Figure 3.4 Gene expression of cyp3a4 in the FETAX experiment.
The genes encoding for Hmgcr also presented significant upregulation of
expression patterns (Figure 3.5). In this case, the control and carrier treatment were not
significantly different from one another, and the lowest treatment of 0.0489 mg L-1. The
highest treatment of 0.1193 mg L-1 was significantly different from all other treatments.
Upregulation of hmgcr expression was dose dependent, however upregulation of
expression patterns was not as extreme as cyp3a4 upregulation. The highest treatment
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saw only 0.6833 upregulation relative to the carrier. This is consistent with a lag time
associated with metabolism and uptake of atorvastatin prior to the distribution of
atorvastatin throughout the circulatory system.
HMGCR Expression
FETAX

1.0

(c)

Fold Change (Log2)

0.8

0.6

(ab)
(b)

0.4

0.2

(a)

0.0

Control

Carrier

0.0489

0.1193

Exposure Concentration (mg/L)

Figure 3.5 hmgcr expression in the FETAX experiment.
Overall, the molecular signature of atorvastatin dosing in humans was confirmed
in the amphibian model. As expected, statistically significant upregulation of cyp3a4 and
hmgcr confirmed uptake and activity of atorvastatin. These data demonstrated Cyp3a4
production increasing with increasing exposure concentrations resulting in statin uptake
into the blood stream. Additionally, hmgcr follows a similar trend of upregulation, and
this linkage confirms that cyp3a4 upregulation is driving hmgcr upregulation as
mevalonate is depleted and additional Hmgcr enzyme is created to attempt to convert
additional mevalonate to fill this gap.
32

3.3.3 Cholesterol ELISA
Whole tissue cholesterol levels were analyzed via Amplex Red Cholesterol
Assay. Samples were first extracted using a chloroform free lipid extraction kit (abcam
#ab211044). Briefly, five tadpoles from each replicate were pooled (n=5) and
homogenized prior to lipid extraction, and pooled samples were then analyzed for total
cholesterol content. Replicates were then combined by treatment and mean cholesterol
concentrations and standard deviation were evaluated against the standard curve
associated with the previously discussed protocol.
Total cholesterol levels in the FETAX experiment showed a reduction in total
cholesterol levels (Figure 3.6). One-way ANOVA with Holm-Sidak pairwise comparison
of measured cholesterol (p < 0.001 F = 56.54, df = 64,) levels in the control and carrier
control were not significantly different indicating the DMSO carrier had no effect on total
cholesterol levels in the tadpoles. The lowest atorvastatin treatment of 0.0142 mg L-1 was
not significantly different from the controls, however all higher concentration treatments
were significantly different from the controls, and each other. This is indicative of the
target action of atorvastatin dosing. These data show that a 96-hour exposure to statins at
concentrations well above environmental relevance can elicit the targeted response of
significant reduction in cholesterol. Furthermore, this reduction is achieved far faster
than the 4-6 week timeframe suggested in the human model (Lennernäs, 2003).
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Figure 3.6 Total cholesterol levels of tadpoles in FETAX.
The number on each bar represents the number of samples represented in the data set.

3.4 Conclusions
The intent of the FETAX in this project was to confirm uptake, activity, and
efficacy of atorvastatin on X. laevis. The data collected and analyzed show that Cyp3a4
mediated uptake of atorvastatin and competitive inhibition of Hmcgr results in dosedependent reduction of total cholesterol levels in tadpoles exposed to atorvastatin. These
results are consistent with the previously discussed molecular and physiological signature
associated with atorvastatin exposure in humans. These results lay the groundwork for
the two follow-on exposures at environmentally relevant concentrations of atorvastatin
and provide baseline reference data for predicting non-target effects of atorvastatin
exposure in X. laevis.
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CHAPTER IV – METAMORPHOSIS ASSAY
4.1 Introduction
The objective of the metamorphosis assay was to evaluate the effects of chronic,
low concentrations of aqueous atorvastatin on developing tadpoles with additional
emphasis on endocrine disruption. This assay used the molecular fingerprint confirmed in
the FETAX to verify atorvastatin exposure and adds additional analysis of cyp19a1 to
evaluate the endocrine disruption potential of atorvastatin exposure. In addition,
morphometric analysis of growth and developmental parameters was used to monitor for
overt endocrine disruption and teratogenesis.
This experiment was a 60-day chronic flow-through exposure and concentrations
for this experiment were 0.2, 0.7, and 0.5 μg L-1 plus a control and there were two
replicates of each concentration (n=40). Mortality was measured for the duration of the
experiment only for confirmation of sub-lethal dosing. Due to the highly lipophilic
nature of atorvastatin, DMSO was used as a solvent to assist the atorvastatin transfer into
water. Atorvastatin was first diluted into DMSO to make the primary stock solution.
The primary stock solution was then further diluted into water to created stock
concentrations at the desired level. The same stock solution was used throughout the
duration of the 60-day chronic exposure. Stock solution was renewed every 48 hours,
and the primary stock was stored at -20 C to prevent degradation for the duration if the
test.
4.2 Endpoints and Protocols
The endpoints for this experiment were morphometric analysis of growth and
developmental parameters, and molecular analysis via qPCR of the previously described
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biomarkers. Due to the small size of post-metamorphosis frogs, it was not possible to
draw blood for cholesterol or steroid analysis.
Molecular biomarkers for this experiment were cpy3a4, hmgcr and cyp19.
Statistical analysis of all qPCR data was performed using a One-way ANOVA with
Holm-Sidak pairwise comparisons. The previously discussed biomarkers of cyp3a4 and
hmgcr were used to evaluate uptake and activity of atorvastatin in this exposure. Since
the post-metamorphosis frogs were too small to collect sufficient quantities of blood for
cholesterol analysis, yet far too large for whole tissue analysis of cholesterol content,
these two biomarkers will serve to confirm the efficacy of atorvastatin in this exposure by
confirming the same directionality of transcriptional dysregulation.
The addition of cyp19a1 as a biomarker to evaluate endocrine disruption allows
additional molecular data to support the morphometric analysis. While the morphometric
analysis can detect overt, severe effects of endocrine disruption, cyp19a1 is far more
sensitive in detection of changing sex steroid levels, an early predictor of endocrine
disruption. As previously discussed, the Cyp19a1 protein is responsible for conversion of
testosterone to estradiol. This conversion happens as a negative feedback loop when
faced with declining estradiol levels. As less estrogen is available to bind the estrogen
receptor, estrogen receptor related proteins dissociate from the estrogen receptor complex
and bind to the promotor region of cyp19a1. This promotes transcription of the Cyp19a1
enzyme to generate more enzyme for conversion of testosterone to estradiol. It is this
negative feedback loop that makes cyp19a1 an attractive biomarker for evaluating
changing sex steroid levels. Upregulation of cyp19a1 will be indicative of activation of
this feedback loop due to declining estradiol levels relative to control.
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Morphometric analysis included measurement of snout-vent length, mass, and NF
stage. Snout-vent length and mass were recorded at experiment termination. Snout-vent
length was measured using stainless steel analog calipers on live frogs. Mass was
recorded by placing the live frog in a tared beaker of water and recording mass. Growth
stage (NF stage) was measured visually by only one observer. As these were post
metamorphosis frogs, microscopy and blind observers were not deemed necessary due
the relative ease of determining growth stage on frogs post-metamorphosis.
4.3 Results and Discussion
4.3.1 Water Chemistry
Water samples were taken at set-up, the midpoint, and termination of the
experiment. These samples were collected directly from the effluent lines for each
replicate tank. The samples were then frozen and shipped to the Mississippi State
Chemical Laboratory for analysis. The results of this independent analysis of atorvastatin
concentrations in test water served to validate test parameters. Figure 4.1 contains
average concentrations and standard deviation (represented by error bars) of atorvastatin
in exposure water. The low treatment was not significantly different, based on One-way
ANOVA (p < 0.001 F = 612.699, df = 23,), from the control, and thus was not used in
follow-on data analysis.
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Atorvastatin Concentration in Exposure Water
Metamorphosis Experiment
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Figure 4.1 Atorvastatin concentrations in exposure water for the metamorphosis
experiment.
The average water quality measurements and standard deviations are reported in
figure 4.2. Water quality parameters were monitored continuously by the toxicology
assay chamber, and randomly verified using hand held equipment daily. Ammonia levels
were 0 ppt for the duration of the experiment and are not represented in graphs. All
treatments were not significantly different from one another with regards to any water
quality parameters.
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Figure 4.2 Exposure tank water quality parameters by treatment.
4.3.2 Molecular Analysis
At termination, liver samples were collected, and flash frozen for follow-on
molecular analysis. The liver tissue was extracted and reverse transcribed following the
previously described protocols.
Expression of cyp3a4 is a biomarker of exposure to atorvastatin. As previously
discussed, cyp3a4 is used an indicator of atorvastatin uptake. Figure 4.3 shows
differential gene expression of cyp3a4 in tadpoles exposed to atorvastatin the
metamorphosis experiment (p < 0.05, F = 12.59, df = 8,). These data indicate slight
upregulation of cyp3a4 relative to control in both the 0.7 and 4.4 ug L-1 concentrations,
however this effect is not statistically significant. The reason for such insignificant
upregulation may be differing exposure routes. As previously discussed, the primary site
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of cyp3a4 mediated uptake occurs in the lining of the digestive tract. This is somewhat
problematic in that the gene expression analyzed here is from liver tissue. However,
studies have shown that cyp3a1 upregulation is also seen in the liver when an organism is
exposed to atorvastatin, but not to the same extent as in digestive tissue. Additionally,
this is an aqueous exposure that is bypassing the digestive tract and entering systemic
circulation via cutaneous respiration as well as uptake at the gills pre-metamorphosis. In
light of this, it is sensible to evaluate cyp3a4 expression levels in the liver, and
unsurprising that very little upregulation of cyp3a4 expression is evident in this exposure.
The 4.4 ug L-1 concentration showed less extreme upregulation than the 0.7 ug L-1
concentration.
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Differential Expression of cyp3a4
Metamorphosis Experiment
60 Day Aquatic Exposure
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Figure 4.3 Differential expression of cyp3a4 in metamorphosing tadpoles exposed to the
indicated concentrations of atorvastatin.
Expression of hmgcr served as a biomarker indicating activity of atorvastatin.
Figure 4.4 shows differential gene expression of hmgcr in tadpoles exposed to
atorvastatin in the metamorphosis experiment (p < 0.05 F = 20.34, df = 8,). These data
indicate upregulation of hmgcr relative to controls for both the 0.7 and 4.4 ug L-1
concentrations. The expression levels were not statistically different from one another
indicating similar activity of atorvastatin despite differences in cyp3a4 expression levels
previously discussed. This upregulation in hmgcr expression levels relative to controls
indicates atorvastatin competitively inhibiting Hmgcr. When viewed in conjunction with
the cyp3a4 data, it becomes apparent that despite atorvastatin bypassing the digestive
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exposure route, cutaneous respiration still allows significant enough levels of atorvastatin
in the blood to maintain efficacy.

Differential Expression of hmgcr
Metamorphosis Experiment
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Figure 4.4 Differential expression of hmgcr in metamorphosing tadpoles exposed to the
indicated concentrations of atorvastatin.
The protein encoded by the cyp19a1 gene is responsible for conversion of
testosterone to estradiol. This gene serves a biomarker indicating dysregulation of the
steroidogenesis pathway. Figure 4.5 shows differential gene expression of cyp19a1 in
liver tissue of post-metamorphosis froglets exposed to atorvastatin through
metamorphosis. These data show statistically significant, dose dependent, upregulation
cyp19a1. As previously stated, this upregulation is indicative of declining estradiol levels
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in the frogs. The dose dependent trend of cyp19a1 indicates that as atorvastatin
concentrations in water increase, the extent to which cyp19a1 transcription is upregulated
also increased. This is occurring despite similar activity levels in hmgcr transcription
rates indicating that while the cholesterol biosynthesis pathway displays a degree of
resistance to dysregulation, the steroidogenesis pathway is still altered dramatically. The
cholesterol biosynthesis pathway is highly conserved and tightly regulated and is
surprisingly resistant to xenobiotic alteration of transcriptional profiles, however, as seen
in these data, only slight alteration of cholesterol biosynthesis is enough to significantly
alter steroidogenesis.

Differential Expression of cyp19a1
Metamorphosis Experiment
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Figure 4.5 Differential expression of cyp19a1 in metamorphosing tadpoles exposed to the
indicated concentrations of atorvastatin.
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4.3.3 Morphometric Analysis
In addition to the previously discussed molecular endpoints, this experiment
included morphometric endpoints. These endpoints were length, mass, and NF stage.
NF stage was measured two times during the experiment, at set-up and take-down.
Figures 4.6 and 4.7 show mean frog length and mass respectively with standard deviation
represented by error bars. These data showed no significant difference in either
endpoints based on One-way ANOVA (p = 0.136 F = 2.01, df = 173) indicating aqueous
exposures at these concentrations have no significant effect on tadpole growth. Figure
4.8 shows mean NF developmental stage of post-metamorphosis tadpoles in this exposure
(n=40/treatment). While a slight downward trend is evident, the difference is not enough
to be statistically significant based on One-way ANOVA (p = 0.981, F = 0.019, df =
119). The lack of error bar on the control is due to the deviation being 0 as all animals in
the control tanks completed metamorphosis. The downward trends in the treated tanks
are driven by a small number of tadpoles that did not complete metamorphosis. As
previously mentioned, this trend was not significant enough to indicate developmental
dysfunction, however, this does warrant further observation in the future.
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Figure 4.6 Mean length and standard deviation of tadpoles treaded with aqueous
atorvastatin (n=40 per treatment).
Mean Frog Mass by Treatment
3.0

2.5

Mass (g)

2.0

1.5

1.0

0.5

0.0
Control

0.7

4.4
-1

Treatment (ug L )

Figure 4.7 Mean wet mass and standard deviation of tadpoles treaded with aqueous
atorvastatin (n=40 per treatment)
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Figure 4.8 Mean NF developmental stage of post-metamorphosis tadpoles exposed to
aqueous atorvastatin.
4.3.4 RNA Sequencing and Bioinformatic Analysis
In addition to the traditional qPCR analysis of gene expression, sequencing of
total RNA transcripts and subsequent bioinformatic analysis was employed for the
metamorphosis assay to evaluate dysregulation of molecular pathways associated with
exposure to aqueous atorvastatin. Figures 4.9 and 4.10 show the top 30 most
dysregulated canonical pathways as determined by IPA analysis of differentially
expressed genes in the data set. The darker orange and red colors indicate activation of
the pathway, and the corresponding shades of blue indicate suppression of the pathway.
The grey bars indicate dysregulation; however, the software was unable to determine
directionality in terms of activation or suppression. This is most often due to individual
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genes in the pathway not behaving as predicted. For instance, if the software sees
upregulation in a specific gene, and predicts corresponding upregulation of a subsequent
gene in response, but instead the data indicate downregulation of that downstream gene,
then the software is unable to determine directionality. This type of result should not be
viewed as a negative result or lack of data, but rather it indicates that the pathway has
been altered, and now it is not behaving as literature predicts is should behave.
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Figure 4.9 Top 30 dysregulated pathways in X. laevis exposed to aqueous atorvastatin
during metamorphosis.
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Figure 4.10 Top 30 dysregulated pathways (continued) in X. laevis exposed to aqueous
atorvastatin during metamorphosis.
These data indicate extensive DNA damage and associated repair mechanisms for
responding to damage. Thirteen of the top 30 significantly dysregulated pathways are
associated with this DNA damage response, indicating extensive DNA damage repair in
metamorphosing tadpoles exposed to aqueous atorvastatin. Additionally, two of the top
30 pathways indicate oxidative stress response. This points to generation of reactive
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oxygen species (ROS) causing DNA damage in exposed tadpoles. The link between
ROS generations and DNA damage is well supported in literature (Friedberg, McDaniel,
& Schultz, 2004), as is the link between atorvastatin and ROS generation (Bouitbir et al.,
2011, 2016). Interestingly, human biomedical literature suggests the opposite effect of
reduction of oxidative stress primarily driven by a reduction in endogenous production of
cholesterol resulting in decreased metabolism of fatty acids and subsequently decreased
generation of ROS (Briones et al., 2009; Ceriello et al., 2005; Sugiyama et al., 2005).
These opposing findings suggest differing responses to atorvastatin in humans versus rats
in the cited studies, and amphibians in this study. This gap in understanding warrants
future investigation into causes of these differing responses.
Additionally, estrogen biosynthesis and aldosterone signaling are upregulated in
the data set supporting the hypothesis of upregulation of the steroidogenesis pathway in
atorvastatin exposure. Furthermore, Figure 4.11 shows the effect of atorvastatin exposure
on master regulators of steroid metabolism. All master regulators in this data set were
significantly upregulated relative to control, further supporting the hypothesis of
upregulation of steroidogenesis concurrent with exposure to environmentally relevant
concentrations of aqueous atorvastatin
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Figure 4.11 Effect of atorvastatin exposure of master regulators of steroid metabolism
with upregulated genes indicated in red.
4.4 Conclusions
The purpose of this assay was to evaluate potential endocrine disrupting effects of
environmentally relevant concentrations of aqueous atorvastatin on tadpoles undergoing
metamorphosis. This experiment used molecular biomarkers previously validated by
FETAX as measures of atorvastatin uptake and activity as well as introducing cyp19a1 as
a biomarker for dysregulation of the steroidogenesis pathway. Additionally,
morphometric analysis of length, mass, and NF developmental stage were used as gross
measurement of endocrine disruption.
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Analysis of molecular biomarker expression levels indicated minimal cyp3a4
mediated atorvastatin uptake. This is unsurprising considering the non-traditional
exposure routes in this assay design. Cutaneous respiration is allowing for atorvastatin
dosing despite lack of digestion. This is allowing sufficient quantities of atorvastatin to
enter the blood stream for drug activity as indicated by the significant upregulation of
hmgcr. Additionally, strong dose-dependent upregulation of cyp19a1 suggests
upregulation of the steroidogenesis pathway and declining estrogen levels corresponding
to atorvastatin dose as previously discussed. This is further supported by RNA
sequencing and bioinformatic analysis. These data showed upregulation of the
aldosterone signaling and estrogen biosynthesis pathway as well as blanket upregulation
of the master regulatory network associated with steroid metabolism.
Additionally, the RNAseq data also suggests significant generation of ROS and
corresponding DNA damage repair. This effect is confirmed in rats, but the opposite
response is seen in human biomedical literature. This differing response warrants further
investigation and suggests a potential non-target effect not evident in humans.
The morphometric analysis of growth and developmental parameters did not show
overt alteration of development suggesting that low concentration transient exposures to
aqueous atorvastatin do not affect amphibian metamorphosis rates. However, the slight
downward trend in NF developmental stage suggests that increased exposure
concentrations or duration could magnify this effect and alter amphibian metamorphosis.
This is particularly likely if tadpoles are exposed to atorvastatin from fertilization to NF
47, which is where this test initiated. Based on these data, environmentally relevant
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concentrations of aqueous atorvastatin have an adverse effect of steroidogenesis by
significantly dysregulating steroidogenesis.
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CHAPTER V – ADULT ASSAY
5.1 Introduction
The purpose of the adult chronic assay was to evaluate potential endocrine
disrupting effects of environmentally relevant concentrations of aqueous atorvastatin in
X. laevis. By sampling at the 4-week and 8-week time points, we add an additional
temporal analysis for better resolution of effects timelines. This assay was performed at
the same environmentally relevant concentrations as the previous metamorphosis
exposure and under the same flow-through conditions. At termination, liver and
digestive tissue, as well as blood, were collected and preserved for future analysis. The
liver and digestive samples were tested for the molecular biomarkers cyp3a4 (digestive),
hmgcr (liver), and cyp19a1 (liver). These biomarkers were used in the previous assays to
evaluate atorvastatin uptake and activity, and dysregulation of steroidogenesis,
respectively. Those biomarkers were employed again in the adult assay for the same
purposes. In addition to the molecular biomarkers, the larger size of adults allows blood
draw and isolation of large enough volumes of plasma to perform additional analysis of
testosterone and estradiol levels as well as total plasma cholesterol concentrations. These
allow for additional investigation into potential endocrine disrupting effects of
atorvastatin exposure on X. laevis.
5.2 Endpoints and Protocols
The endpoints for this assay were qPCR analysis of selected genes, hormone
analysis of testosterone and estradiol, and plasma cholesterol quantitation. As previously
discussed, the molecular biomarkers employed for this assay have particular molecular
signatures that are useful in evaluating and confirming atorvastatin dosing. Statistical
54

analysis of all qPCR data was performed using a One-way ANOVA with Holm-Sidak
pairwise comparisons. When dosed with atorvastatin, the expected response is
transcriptional upregulation of cyp3a4 and hmgcr in digestive and liver tissue,
respectively. Previously, atorvastatin exposure caused transcriptional upregulation of
cyp19a1 and I anticipated a similar response in adults.
With the additional ability to collect plasma from blood samples, additional
assays were performed to measure testosterone, estradiol, and total cholesterol
concentrations in plasma. The testosterone and estradiol ELISA kits were previously
validated for use in X. laevis using total cholesterol collected from whole body tissue of
tadpoles from the FETAX experiment. The Amplex Red Cholesterol Assay was
validated from the manufacturer for use in X. laevis, and additional validation was
deemed unnecessary. Due to the extremely low concentrations of estradiol in males, and
testosterone in females, it was not possible to test for opposing sex steroids. Thus, males
were evaluated for testosterone concentrations, and females were evaluated for estradiol
concentrations.
I anticipated a decline in testosterone and estradiol levels in both males and
females, respectively, and large individual variability with respect to female estradiol
concentrations. Frogs were shipped on ice overnight and thawed upon receipt then
acclimated to the exposure chamber for 7 days under clean flow-through conditions.
While this is not a perfect solution, I hope that the cold snap served to “reset” the
ovulatory cycle in females to allow for similar ovulatory cycles during the 60-day
exposure.
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It was expected that total plasma cholesterol concentrations would decline when
exposed to atorvastatin. The aqueous atorvastatin concentrations tested were several
orders of magnitude below the equivalent recommended therapeutic dose in humans.
Additionally, the exposure route bypassed the digestive system as with the
metamorphosis exposure. Previously the transcriptional upregulation of cyp19a1 had a
very significant response to a relatively minor dysregulation of cholesterol biosynthesis.
Based on this observation, even the slightest alteration of total cholesterol concentrations
would significantly alter steroidogenesis.
5.3 Results
5.3.1 Water Chemistry
The adult chronic assay and metamorphosis assay were run in conjunction with
one another, and as such, water quality was monitored continuously across both
experiments to keep water chemistry parameters as well as atorvastatin concentrations
consistent across both experiments. Figure 5.1 shows recorded water quality parameters
and standard deviation. No water quality parameters were significantly different across
any treatments or replicates.
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Figure 5.1 Exposure tank water quality parameters by treatment.
Similar to the metamorphosis experiment, water samples were collected at set-up,
week-4, and termination (week-8). These samples were shipped to Mississippi State
Chemical Laboratory for validation of exposure concentrations using the previously
described protocol. Figure 5.2 shows atorvastatin concentrations in exposure water by
treatment. All concentrations were significantly different from the other treatments.
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Figure 5.2 Atorvastatin concentration in exposure water by treatment.
5.3.2 Molecular Analysis
At termination, samples of liver and digestive tissue were collected, and flash
frozen for later use in qPCR. These samples were then extracted and analyzed following
the previously described protocols. The digestive tissue was analyzed for expression
levels of cyp3a4, and the liver tissue was analyzed for hmgcr and cyp19a1. Additionally,
these data are further subdivided into 4-week and 8-week sampling points. This sampling
design allows for temporal analysis of exposure effects.
Expression levels of cyp3a4 in digestive tissue is a biomarker of atorvastatin
uptake as previously demonstrated. These data show statistically significant upregulation
relative to control of cyp3a4 at both the 4-week and the 8-week sampling point (Figure
5.3) (p < 0.001, F = 110.96.5, df = 8).
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Figure 5.3 Relative gene expression of cyp3a4 in digestive tissue of X. laevis exposed to
atorvastatin.
The 8-week sampling point shows a reduced upregulation significantly different from the
4-week sampling point indicating temporal differences in expression levels relative to
control. These data are consistent with previous observations from the metamorphosis
assay as well as the FETAX. It is of note that this upregulation is much higher than
previously seen in the metamorphosis exposure despite similar exposure routes of
primarily cutaneous respiration supplemented with digestion. One possible reason for
differences in cyp3a4 expression magnitude is lipid differences in food. Tadpoles and
metamorphosing frogs are primarily filter feeders. At this age stage, their diet consists
primarily of powdered algae dissolved in water. Adult frogs, however, were fed Xenopus
Diet (Zeigler). This scientifically formulated diet has more fat content, and given the
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high lipophilicity of atorvastatin, it is unsurprising that we would see increased binding to
food relative to algae contributing to increased upregulation of cyp3a4. This statistically
significant upregulation of cyp3a4 indicates that atorvastatin uptake is occurring in the
adult frogs.
Expression levels of hmgcr in liver tissue is a biomarker of atorvastatin activity.
These data indicate statistically significant (p < 0.001 F = 76.074, df = 8), dose dependent
upregulation of hmgcr at the 4-week time point, however, this effect is abolished over
time (Figure 5.4). This indicates strong and rapid return to baseline expression levels as
the enzyme reaches saturation. This threshold effect does not indicate reactivation of
endogenous cholesterol production, rather it indicates the beginning of acclimation to
continued inhibition of cholesterol biosynthesis.
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Figure 5.4 Relative gene expression of hmgcr in liver tissue of X. laevis exposed to
atorvastatin.
Expression levels of cyp19a1 in liver tissue is a biomarker of steroidogenesis
dysregulation. Figure 5.5 shows cyp19a1 expression levels in adult X. laevis exposed to
aqueous atorvastatin. These data show statistically significant, dose dependent
upregulation at the 4-week sampling point, with an even more pronounced effect at the 8week sampling point (p = 0.002 F = 22.84, df = 8). This is indicative of rapid, significant
dysregulation of steroidogenesis with the effect increasing over time and with dose. As
previously discussed, this response is associated with increase conversion of testosterone
to estradiol consistent with declining estradiol levels.
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Figure 5.5 Relative gene expression of cyp19a1 in liver tissue of X. laevis exposed to
atorvastatin.
In its entirety, this molecular fingerprint is consistent with previous data
indicating uptake and activity of atorvastatin. Despite the uptake and activity biomarkers
indicating acclimation to atorvastatin dosing occurring around the 4-week time point, the
upregulation of steroidogenesis persists and continues to increase by week 8. This effect
further highlights how a minor inhibition of cholesterol biosynthesis significantly
contributes to dysregulation of steroidogenesis.
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5.3.3 Hormone Analysis
Samples collected at both the four- and eight-week time points were analyzed via
ELISA using the previously described protocol. Plasma samples were isolated from
collected blood via centrifuge and were analyzed for testosterone concentration in males
and estradiol concentration in females.
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Figure 5.6 Plasma testosterone concentrations relative to control in adult male X. laevis
exposed to aqueous atorvastatin sampled at multiple time points.
Figure 5.6 shows testosterone concentrations by treatment relative to control at
both the four and eight-week sampling points. At the four-week time point, testosterone
concentrations were not significantly different from control (p = 0.01, F = 10.94, df = 8).
At the eight-week time point, testosterone concentrations differed significantly from
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control. In the 0.7 ug L-1 treatment, testosterone concentrations were increased
significantly relative to control and the high treatment. Control frogs had a mean plasma
testosterone concentration of 1.09±0.27 ng L-1(n=3) and the 0.7 ug L-1 atorvastatin
treatment had a mean plasma testosterone concentration of 8.27±1.82 ng L-1(n=3). This
is a 658% increase in plasma testosterone concentrations at the lower atorvastatin
treatment in the assay. The higher 4.4 ug L-1 treatment was also significantly increased
relative to control although not to the extreme that the lower treatment was increased.
The mean plasma testosterone concentration in the higher treatment was 3.15±0.60 ng L1

, an increase of 189% relative to control. These data indicate that at 4 weeks, plasma

testosterone concentrations were unaffected by atorvastatin, however, at the 8-week time
point, elevated testosterone levels are evident with the greatest magnitude of change in
the mid treatment. This lag in testosterone production is unsurprising as males will have
significant enough quantities Cyp19a1 to sustain testosterone conversion for a
considerable amount of time before additional protein production is required. This is
likely resulting in an overcorrection in treated groups due to the previously seen increase
in cyp19a1 expression over time. While these data are not sufficient to predict a decline
in estradiol levels, they are significant enough to indicate an endocrine disrupting effect
in male frogs exposed to environmentally relevant concentration of aqueous atorvastatin.
As previously discussed, the significant upregulation of cyp19a1 points to a
potential alteration in plasma estradiol levels increasing in severity as atorvastatin dose
increases. Plasma estradiol concentrations of adult females exposed to atorvastatin are
shown relative to control in Figure 5.7.
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Figure 5.7 Plasma estradiol concentrations relative to control in adult female X. laevis
exposed to aqueous atorvastatin sampled at multiple time points.
A similar dose response to the male testosterone levels is present in the lower 0.7 ug L-1
treatment. Mean plasma estradiol concentrations were increase substantially at the fourweek time point. Unlike the male testosterone levels, however, there is a significant
decrease in circulating estradiol levels in the higher treatment at the 4-week time point
with the decline continuing into the eight-week time point. These data strongly correlate
with the strong, dose dependent upregulation of cyp19a1 in the highest treatment and
confirms predictions of dysregulation of steroidogenesis accompanied by a significant
decline in circulating estradiol levels at 4.4 ug L-1 concentrations. The 0.7 ug L-1
treatment shows significantly increased plasma estradiol concentrations with the effect
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declining with time. While this is contradictory to expectations, it can be explained
primarily by gender differences in the frogs.
As discussed in the materials and methods, adult female X. laevis are twice the
size of their male counterparts. The males used in this assay were 50±1 g and the females
used in this experiment were 100±1 g in mass. This drastic mass difference will drive a
different dose response relationship in males versus females when exposed to the same
dose. This affects two main dose response relationships. As cutaneous respiration
accounts, at least in part, for atorvastatin uptake, body mass to surface area ratio is of
significance. It is well known that as mass increases in an organism, the surface area to
volume ratio decreases. This is beneficial for uptake via cutaneous respiration as the
larger female frogs will experience reduced uptake when compared to their male
counterparts.
Additionally, the increased mass of the female frogs means that they must receive
a higher dose per organism to match the dose of their male counterparts. The goal of this
experiment was environmental relevance, as such, the aqueous dose administered was
based on environmentally relevant concentrations rather than equivalent dosing by mass.
This means that the dose received by the female frogs was lower than the dose received
in the male frogs. The threshold effect previously described in the hmgcr data indicate
that at the lower concentrations, the larger females received a lower dose per body mass
allowing compensation of endocrine disrupting effects. In contrast, the threshold was
breached in the higher concentration resulting in the non-target effects previously
described.
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5.3.4 Cholesterol Analysis
In addition to sex steroid analysis, plasma cholesterol levels were also evaluated.
The protocol for the Amplex Red cholesterol assay has been previously discussed.
Simply put, this colorimetric assay is capable of determining free and bound cholesterol
in plasma and was previously validated for use with X. leavis.
Figure 5.8 shows plasma cholesterol concentrations in males exposed to aqueous
atorvastatin for 60 days. Plasma cholesterol concentrations were significantly reduced at
both the four- and eight-week time-points (p < 0.001, F = 42.26, df = 8). In general, the
higher treatment saw a lesser reduction, however across all treatments and time points
plasma cholesterol levels were significantly lower than control suggesting targeted effects
of atorvastatin correlating with increased uptake and activity relative to control. Based
on these data, male frogs exposed to atorvastatin experience hypocholesterolemia relative
to control when exposed to environmentally relevant concentrations of aqueous
atorvastatin.
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Figure 5.8 Plasma cholesterol concentrations relative to control in adult male X. laevis
exposed to aqueous atorvastatin sampled at multiple time points.
Plasma cholesterol concentrations for the females showed a very different effect.
Figure 5.9 shows plasma cholesterol concentrations relative to control in adult female X.
laevis exposed to aqueous atorvastatin (p < 0.001, F = 51.76, df = 8). Only the lower 0.7
ug L-1 treatment showed a reduction in plasma cholesterol and only at the 4-week time
point. Plasma cholesterol was reduced 24.5% from 1449.57±28.29 ug mL-1 to
1093.32±20.70 ug mL-1 relative to control. This reduction was completely abolished by
the eight-week time point and showed an increase of 630% to 2876.17±99.00 ug mL-1.
The higher 4.4 ug L-1 treatment showed increases of 35% at four weeks to 1962.9±28.36
ug mL-1 and a 16% increase at eight weeks to 2047.58±84.50 ug mL-1 relative to controls.
As previously discussed, it is possible that the larger mass of the female frogs contributed
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to a lower overall dose received relative to body mass. This dose may have been
sufficiently low enough to fail to elicit target effects in the female frogs. The cholesterol
response from the females in this experiment may have been a byproduct of non-target
effects which have been previously shown in this study to be quite dramatic despite
relatively minor dysregulation of cholesterol biosynthesis.
Plasma Cholesterol Concentrations by Treatment
Adult Chronic (Female Only)

Plasma Cholesterol Concentration (ug/mL)

1400
Conc @ 4 weeks
Conc @ 8 weeks

(c)

1200
1000
800
600

(d)
(e)

400
200
(a)

(a)

0
-200
-400

(b)

-600
Control

0.7

4.4
-1

Treatment (ug L )

Figure 5.9 Plasma cholesterol concentrations relative to control in adult female X. laevis
exposed to aqueous atorvastatin sampled at multiple time points.
5.4 Conclusions
The goal of the adult chronic assay was to evaluate potential endocrine disrupting
effects of aqueous exposure to environmentally relevant concentrations of atorvastatin at
multiple time points in adult males and female X. laevis. The endpoints measured for this
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assay were transcriptional regulation of cyp3a4, hmgcr, and cyp19a1 as well as
measurement of plasma cholesterol, testosterone, and estradiol concentrations.
The molecular signature in this assay confirmed atorvastatin uptake and activity
by cyp3a4 and hmgcr transcriptional upregulation particularly at the 4-week time point.
This effect diminished at the 8-week time point. Despite this, cyp19a1 upregulation
continued to increase through the 8-week time point indicating dysregulation of
steroidogenesis and declining estradiol concentrations.
Plasma testosterone and estradiol concentrations were evaluated to confirm nontarget effects of atorvastatin predicted by the upregulation of cyp19a1. Testosterone
concentrations in males were unchanged relative to control at the 4-week time point with
elevated testosterone levels by week 8. It is hypothesized that this increase is a byproduct
of increased testosterone production consistent with general upregulation of
steroidogenesis. This hypothesis is further supported by the plasma estradiol
concentrations measured in this experiment. Plasma estradiol was elevated in the lower
atorvastatin dose and significantly decreased in the higher treatment. The differences in
this response are hypothesized to be due primarily to the larger mass of female X. laevis
contributing to a reduced dose per body mass. It is believed that this reduced dose failed
to achieve the threshold necessary to elicit non-target effects.
Plasma cholesterol concentrations confirmed target effects in males with
significant reduction in circulation cholesterol increasing over time. However, the female
cholesterol concentrations increased with atorvastatin dosing in all but the low treatment
and only at the 4-week time point. This effect further confirms the hypothesis that the
larger mass of females allows them to withstand higher concentrations of atorvastatin
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before target effects are apparent. Taken into context with the previously discussed
estradiol data, it appears that the threshold for eliciting non-target effects of reduced
plasma estradiol is lower than the threshold to elicit target effects of reduction of
circulating cholesterol.
The data from this assay indicate environmentally relevant concentrations of
aqueous atorvastatin have an adverse effect of steroidogenesis by significantly
upregulating conversion of testosterone to estradiol in the face of declining estradiol
levels. This effect is more pronounced in males primarily due to their smaller size.
Female X. laevis demonstrate a greater tolerance for aqueous atorvastatin with target
effects not apparent in this assay, and non-target effects appearing only in the 4.4 ug L-1
treatment. This supports the hypothesis the aqueous atorvastatin has endocrine disrupting
potential at environmentally relevant concentrations.
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CHAPTER VI – CONCLUSION
This research investigated the non-target effects of exposure to environmentally
relevant concentrations of aqueous atorvastatin. Previous research has shown that
wastewater treatment plants do not sufficiently remove atorvastatin from wastewater
during the treatment process(Halling-Sørensen et al., 1998; Jelic et al., 2011; Lee et al.,
2009; Ort et al., 2010) resulting in discharge of atorvastatin in wastewater effluent at or
below 2ug L-1(Jelic et al., 2011; Lee et al., 2009). I hypothesize that these low
concentrations of aqueous atorvastatin are sufficient to elicit the non-target effects of
alteration of circulating testosterone and estradiol as a consequence of inhibition of
endogenous production of cholesterol potentially resulting in alteration of growth,
development, and sexual differentiation in amphibians localized near wastewater effluent
sites.
This research sought to investigate these non-target effects using traditional
aquatic toxicology assays combined with modern molecular biology techniques to
identify and report regulatory alteration of physiological pathways in a model amphibian,
Xenopus laevis. This was investigated via three primary assays. First, a modified
FETAX assay was employed to evaluate the target and non-target effects of atorvastatin
exposure at high concentrations on developing tadpoles. Second, the molecular
fingerprint developed from the FETAX assay was used to verify exposure effects of
chronic exposure to aqueous atorvastatin at environmentally relevant concentrations on
metamorphosing tadpoles. Finally, a chronic adult exposure at environmentally relevant
concentrations was used to determine the non-target effects of atorvastatin exposure on
circulating testosterone and estradiol concentrations in amphibians.
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The results of the FETAX validated biomarkers of uptake, activity and efficacy of
atorvastatin in X. laevis. These biomarkers were upregulation of cyp3a4, and hmgr for
uptake and activity respectively, and efficacy was validated by significant reduction in
total cholesterol. The directionality of this dysregulation was consistent with the
response of the same biomarkers in humans administered atorvastatin as treatment for
hypercholesterolemia. These data confirm that atorvastatin has the potential to elicit the
same targeted responses to atorvastatin exposure as humans.
Investigation into non-target effects of atorvastatin at environmentally relevant
concentrations began with the chronic metamorphosis assay. The results of this assay
indicated significant upregulation of biomarkers related to inhibition of cholesterol
biosynthesis and showed dose-dependent upregulation of cyp19a1 suggesting a molecular
response to declining estrogen concentrations. This non-target effect was confirmed via
total RNA sequencing, and showed significant upregulation of master regulators
associated with steroid metabolism. Furthermore, RNA sequencing confirmed activation
of the canonical pathways for estrogen biosynthesis and aldosterone signaling.
Combined, these data indicate that exposure to aqueous atorvastatin alters steroidogenesis
and results in declining sex steroid concentrations consistent with findings in zebrafish
exposed to atorvastatin(Al-Habsi et al., 2015).
Morphometric analysis of length, mass and developmental stage did not indicate
overt alteration of growth or development suggesting that transient exposure to
environmentally relevant concentrations of atorvastatin was not sufficient to alter growth
and development, however the data do suggest that longer term exposures or higher
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concentrations may still alter rates of metamorphosis highlighting a need for further study
into complete life cycle exposures.
Additionally, RNA sequencing confirmed generation of ROS and concurrent
DNA damage repair consistent with findings from other researchers (Bouitbir et al.,
2011, 2016). This response is contradictory to findings in the medical community
suggesting that atorvastatin serves to ameliorate the effects of ROS generation and
oxidative stress(Briones et al., 2009; Ceriello et al., 2005; Sugiyama et al., 2005). These
contradictory findings suggest a potential difference in the response of humans versus
amphibians exposed to atorvastatin and warrant future investigation into these
differences.
Circulating cholesterol concentrations in males and females exposed to
atorvastatin are indicative of targeted effects of atorvastatin exposure. Male X. laevis
showed a dose-dependent and time dependent reduction in circulating cholesterol
indicating the targeted effect of atorvastatin exposure is evident in in the smaller males
even at the low environmentally relevant concentrations. Cholesterol concentrations in
females show a general increase in cholesterol concentrations suggesting that the larger
body mass of females provide some degree of protection from targeted effects of
atorvastatin exposure at environmentally relevant concentrations. These sexual
differences in body mass are also evident in testosterone and estradiol concentrations as
well.
The adult chronic assay further confirms findings from the metamorphosis assay
with relation to dysregulation of steroidogenesis. These data show strong, dosedependent upregulation of steroidogenesis and declining estradiol concentrations in adult
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female X. laevis at 4.4 ug L-1. While the lower 0.7 ug L-1 did not show a decrease in
circulating estradiol concentration, this is believed to be an artifact of mass differences in
adult males and females as female X. laevis are significantly larger than their male
counterpart. This may result in female X. laevis receiving a lower dose per body mass
resulting in decreased non-target effects at lower concentrations. Testosterone
concentrations in males were unaffected at 4-weeks, with elevated testosterone
concentrations at 8-weeks. These findings suggest that testosterone concentrations are
unaffected in the short term and are unsurprising given the increased capacity for
testosterone production in males of any species. Relative to control, adult males and
females show alteration of hormone level inconsistent with predictions suggesting that
dysregulation of steroidogenesis is occurring in frogs exposed to atorvastatin in an
unpredictable manner. The directionality of this dysregulation is inconsistent with
predictions indicating the need for further research into the exact nature of this
dysregulation.
This research provides further insight into the potentially harmful non-target
effects of relatively low concentrations of aqueous atorvastatin discharged in bodies of
water inhabited by amphibians. The data indicate significant dose-dependent
upregulation of steroidogenesis as confirmed by both qPCR and total RNA sequencing.
While these data do not indicate overt morphological alteration of metamorphosis in
these short exposures, on a molecular level, the early indicators of endocrine disruption
are evident, and this conclusion is further supported by alteration of testosterone and
estradiol concentration in adults. While it was not possible to measure testosterone and
estradiol concentrations in metamorphosing tadpoles, the increased sensitivity of earlier
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life stages to aquatic toxins combined with the molecular signature indicating
upregulation of steroidogenesis suggest that alteration of sex steroid levels is occurring
and has the potential to significantly alter sex ratios in populations localized around
wastewater effluent sites. Based on these data, I fail to reject the hypothesis that
environmentally relevant concentrations of aqueous atorvastatin are sufficient to elicit the
non-target effects of alteration of circulating testosterone and estradiol as a consequence
of inhibition of endogenous production of cholesterol potentially resulting in alteration of
growth, development, and sexual differentiation in amphibians.
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